Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients With Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
-
-
Arkansas
-
Jonesboro, Arkansas, United States, 72401
-
Little Rock, Arkansas, United States, 72205
-
-
California
-
Roseville, California, United States, 95661
-
San Francisco, California, United States, 94115
-
-
Colorado
-
Englewood, Colorado, United States, 80113
-
Wheat Ridge, Colorado, United States, 80033
-
-
Connecticut
-
Bridgeport, Connecticut, United States, 06606
-
Hamden, Connecticut, United States, 06518
-
-
Florida
-
Clearwater, Florida, United States, 33765
-
Gainesville, Florida, United States, 32607
-
Gainesville, Florida, United States, 32610
-
Hollywood, Florida, United States, 33021
-
Jacksonville, Florida, United States, 32256
-
Jacksonville, Florida, United States, 32224
-
Miami, Florida, United States, 33173
-
North Miami Beach, Florida, United States, 33162
-
Winter Park, Florida, United States, 32789
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
-
Atlanta, Georgia, United States, 30308
-
Atlanta, Georgia, United States, 30309
-
Conyers, Georgia, United States, 30012
-
Marietta, Georgia, United States, 30060
-
Savannah, Georgia, United States, 31405
-
-
Illinois
-
Arlington Heights, Illinois, United States, 60005
-
Moline, Illinois, United States, 61265
-
Rockford, Illinois, United States, 61107
-
-
Indiana
-
Columbus, Indiana, United States, 47201
-
Indianapolis, Indiana, United States, 46237
-
Indianapolis, Indiana, United States, 46202-5250
-
-
Iowa
-
Clive, Iowa, United States, 50325
-
Davenport, Iowa, United States, 52807
-
-
Kansas
-
Overland Park, Kansas, United States, 66212
-
Topeka, Kansas, United States, 66606
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
-
-
Maryland
-
Annapolis, Maryland, United States, 21401
-
Chevy Chase, Maryland, United States, 20815
-
Lutherville, Maryland, United States, 21093
-
Silver Spring, Maryland, United States, 20901
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
-
Boston, Massachusetts, United States, 02118
-
Burlington, Massachusetts, United States, 01805
-
-
Michigan
-
Troy, Michigan, United States, 48098
-
-
Minnesota
-
Plymouth, Minnesota, United States, 55446
-
-
Mississippi
-
Picayune, Mississippi, United States, 39466
-
-
Missouri
-
Kansas City, Missouri, United States, 64131
-
Mexico, Missouri, United States, 65265-3726
-
St. Louis, Missouri, United States, 63128
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
-
-
New Jersey
-
Egg Harbor Township, New Jersey, United States, 08234
-
Glen Ridge, New Jersey, United States, 07028
-
Manalapan, New Jersey, United States, 07726
-
-
New York
-
Great Neck, New York, United States, 11021
-
Lake Success, New York, United States, 11042
-
New York, New York, United States, 10021
-
New York, New York, United States, 10022
-
New York, New York, United States, 10028
-
New York, New York, United States, 10128
-
Rochester, New York, United States, 14607
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
-
Charlotte, North Carolina, United States, 28211
-
Jacksonville, North Carolina, United States, 28546
-
Rocky Mount, North Carolina, United States, 27804
-
Wilmington, North Carolina, United States, 28401
-
Wilmington, North Carolina, United States, 28403
-
-
Ohio
-
Beachwood, Ohio, United States, 44122
-
Cincinnati, Ohio, United States, 45220
-
Cincinnati, Ohio, United States, 45242
-
Cincinnati, Ohio, United States, 45219
-
Cleveland, Ohio, United States, 44195
-
Warren, Ohio, United States, 44484
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74104
-
Tulsa, Oklahoma, United States, 74135
-
-
Oregon
-
Portland, Oregon, United States, 97225
-
Portland, Oregon, United States, 97220
-
-
Pennsylvania
-
Beaver Falls, Pennsylvania, United States, 15010
-
Duncansville, Pennsylvania, United States, 16635
-
Philadelphia, Pennsylvania, United States, 19107
-
Pittsburgh, Pennsylvania, United States, 15232
-
Pittsburgh, Pennsylvania, United States, 15224
-
Pittsburgh, Pennsylvania, United States, 15243
-
Sayre, Pennsylvania, United States, 18840
-
-
South Carolina
-
Columbia, South Carolina, United States, 29204
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
-
Chattanooga, Tennessee, United States, 37403
-
Germantown, Tennessee, United States, 38138
-
-
Texas
-
Austin, Texas, United States, 78745
-
-
Utah
-
South Ogden, Utah, United States, 84405
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
-
-
Washington
-
Bellevue, Washington, United States, 98004
-
Seattle, Washington, United States, 98101
-
Spokane, Washington, United States, 99204
-
Vancouver, Washington, United States, 98664
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
-
Milwaukee, Wisconsin, United States, 53233
-
Milwaukee, Wisconsin, United States, 53215
-
Monroe, Wisconsin, United States, 53566
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient diagnosed with moderate to severe Crohn's Disease.
- Failed prior infliximab therapy.
- Patient is judged to be in generally good health as determined by the principal investigator.
Exclusion Criteria:
- Previous treatment with adalimumab.
- Patient considered by the investigator, for any reason, to be an unsuitable candidate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
AEs, laboratory data, physical examinations and vital signs
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Efficacy variables will be assessed from Outcomes Questionnaires
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- M06-808
- CHOICE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.